14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 -- Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in JAMA Surgery.
Minji Kim, Pharm.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues characterized the use of and factors associated with GLP-1 RA initiation among U.S. adults undergoing bariatric surgery in a retrospective cohort study. Electronic health records were obtained from about 113 million U.S. adults.
The researchers found that 14.0 percent of the 112,858 individuals undergoing bariatric surgery initiated GLP-1 RAs after surgery, with 21.5 percent beginning within two years of surgery and the remainder initiating during postsurgical years 3 to 4, 5 to 6, or beyond (32.3, 25.2, and 21.0 percent, respectively). Compared with their counterparts, female patients, those undergoing sleeve gastrectomy, and those with type 2 diabetes were more likely to initiate GLP-1 RAs (adjusted hazard ratios, 1.61, 1.42, and 1.34, respectively). There was an 8 percent increase in the likelihood of GLP-1 RA initiation with each one-unit increase in postsurgical body mass index (BMI; adjusted hazard ratio, 1.08).
“These findings raise important questions for future obesity research,” senior study author Hemalkumar Mehta, Ph.D., also from the Johns Hopkins Bloomberg School of Public Health, said in a statement. “For example, what is the optimal clinical threshold for prescribing a GLP-1 in terms of timing and the patient’s relative weight after bariatric surgery?”
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
THURSDAY, Sept. 25, 2025 -- For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater...
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
THURSDAY, Sept. 25, 2025 -- Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online...
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 -- In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.